Membrane proteomics for leukemia classification and drug target identification

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 6, 2009, Pages 603-610

  Kohnke, Philippa L ^a   Mulligan, Stephen P ^b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biomarker; Leukemia; MAb; Plasma membrane; Proteomics

Indexed keywords

ALEMTUZUMAB; DASATINIB; GEMTUZUMAB OZOGAMICIN; IMATINIB; LUMILIXIMAB; MEMBRANE PROTEIN; NILOTINIB; RITUXIMAB;

B CELL LYMPHOMA; CELL MEMBRANE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL MEMBRANE; HUMANS; LEUKEMIA; LYMPHOMA; MEMBRANE PROTEINS; PROTEOME; PROTEOMICS;

EID: 72449200207     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Robak T: Novel drugs for chronic lymphoid leukemias: Mechanism of action and therapeutic activity. Curr Med Chem (2009) 16(18):2212-2234.
2. Tsiftsoglou AS, Bonovolias ID, Tsiftsoglou SA: Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy. Pharmacol Ther (2009) 122(3):264-280.
3. Van Bockstaele F, Verhasselt B, Philippe J: Prognostic markers in chronic lymphocytic leukemia: A comprehensive review. Blood Rev (2009) 23(1):25-47.
4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 343(26):1910-1916. (Pubitemid 32064784)
5. Raguz S, Yagüe E: Resistance to chemotherapy: New treatments and novel insights into an old problem. Br J Cancer (2008) 99(3):387-391.
6. Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol (2005) 1(5):252-262.
7. Tan S, Tan HT, Chung MCM: Membrane proteins and membrane proteomics. Proteomics (2008) 8(19):3924-3932.
8. Cordwell SJ, Thingholm TE: Technologies for plasma membrane proteomics. Proteomics (2009):doi:10.1002/pmic.200900521
9. Pleyer L, Egle A, Hartmann TN, Greil R: Molecular and cellular mechanisms of CLL: Novel therapeutic approaches. Nat Rev Clin Oncol (2009) 6(7):405-418.
10. Stevenson FK, Caligaris-Cappio F: Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood (2004) 103(12): 4389-4395. (Pubitemid 38745961)
11. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F: The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood (2009) 114(16):3367-3375.
12. Lee EJ, Lean CB, Limenta LM: Role of membrane transporters in the safety profile of drugs. Expert Opin Drug Metab Toxicol (2009) 5(11):1369-1383.
13. Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood (2008) 111(8):3941-3967.
14. Almén MS, Nordström KJ, Fredriksson R, Schiöth HB: Mapping the human membrane proteome: A majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol (2009) 7(1):50.
15. Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta (2008) 1785(2): 182-206.
16. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun (2005) 8:140-174.
17. Gribben JG, Hallek M: Rediscovering alemtuzumab: Current and emerging therapeutic roles. Br J Haematol (2009) 144(6): 818-831.
18. Sperandio M, Gleissner CA, Ley K: Glycosylation in immune cell trafficking. Immunol Rev (2009) 230(1):97-113.
19. Peracaula R, Barrabés S, Sarrats A, Rudd PM, de Llorens R: Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers (2008) 25(4-5):207-218.
20. Bennett F, Rawstron A, Plummer M, de Tute R, Moreton P, Jack A, Hillmen P: B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br J Haematol (2007) 139(4): 600-604.
21. Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D: Doubling time of soluble CD23: A powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia (2008) 22(10):1882-1890.
22. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J: Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood (2008) 111(3):1594-1602.
23. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, Hamblin TJ, Devereux S: CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood (2008) 111(10):5173-5181.
24. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, Rossi D et al: CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/ vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res (2009) 69(9):4001-4009.
25. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F: CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med (2008) 14(5):210-218.
26. Macher BA, Yen TY: Proteins at membrane surfaces - A review of approaches. Mol Biosyst (2007) 3(10):705-713.
27. Josic D, Clifton JG: Mammalian plasma membrane proteomics. Proteomics (2007) 7(16):3010-3029.
28. Lu B, McClatchy DB, Kim JY, Yates JR 3rd: Strategies for shotgun identification of integral membrane proteins by tandem mass spectrometry. Proteomics (2008) 8(19):3947-3955.
29. Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K: Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 8(7):1501-1515.
30. Miguet L, Béchade G, Fornecker L, Zink E, Felden C, Gervais C, Herbrecht R, van Dorsselaer A, Mauvieux L, Sanglier-Cianferani S: Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J Proteome Res (2009) 8(7):3346-3354.
31. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE et al: Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2003) 278(9):7607-7616.
32. Lee SJ, Kim KH, Park JS, Jung JW, Kim YH, Kim SK, Kim WS, Goh HG, Kim SH, Yoo JS, Kim DW et al: Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines. Biochem Biophys Res Commun (2007) 357(3):620-626.
33. Wei X, Li L: Comparative glycoproteomics: Approaches and applications. Brief Funct Genomic Proteomic (2009) 8(2):104-113.
34. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol (2009) 27(4):378-386.
35. Ellmark P, Woolfson A, Belov L, Christopherson RI: The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease. Methods Mol Biol (2008) 439:199-209.
36. Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, Chrisp JS, Sewell WA, Bradstock KF, Bendall L, Pascovici DS et al: Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol (2006) 135(2):184-197.
37. Barber N, Gez S, Belov L, Mulligan SP, Woolfson A, Christopherson RI: Profiling CD antigens on leukaemias with an antibody microarray. FEBS Lett (2009) 583(11):1785-1791.
38. Fulda S: Cell death in hematological tumors. Apoptosis (2009) 14(4):409-423.
39. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Köcher T, Mechtler K, Bennett KL, Superti-Furga G: Charting the molecular network of the drug target Bcr-abl. Proc Natl Acad Sci USA (2009) 106(18):7414-7419.
40. Schenone S, Bruno O, Radi M, Botta M: New insights into small-molecule inhibitors of Bcr-abl. Med Res Rev (2009):doi:10.1002/med.20175
41. Thingholm TE, Jensen ON, Larsen MR: Analytical strategies for phosphoproteomics. Proteomics (2009) 9(6):1451-1468.
42. Pan C, Olsen JV, Daub H, Mann M: Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics (2009): epub ahead of print.
43. Schiess R, Wollscheid B, Aebersold R: Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol (2009) 3(1):33-44.
44. Hanash SM, Pitteri SJ, Faca VM: Mining the plasma proteome for cancer biomarkers. Nature (2008) 452(7187):571-579.
45. Albitar M, Potts SJ, Giles FJ, O'Brien S, Jilani I, Donahue AC, Estey EH, Kantarjian H: Proteomics-based prediction of clinical response in acute myeloid leukemia. Exp Hematol (2009) 37(7):784-790.
46. Weiner GJ: Monoclonal antibody mechanisms of action in cancer. Immunol Res (2007) 39(1-3):271-278.
47. Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E: Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther (2009) 9(2):207-220.
48. Petrelli A, Valabrega G: Multitarget drugs: The present and the future of cancer therapy. Expert Opin Pharmacother (2009) 10(4):589-600.
49. Burger JA, Peled A: CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia (2009) 23(1):43-52.
50. Béné MC, Kaeda JS: How and why minimal residual disease studies are necessary in leukemia: A review from WP10 and WP12 of the European LeukaemiaNet. Haematologica (2009) 94(8):1135-1150.
51. Campana D: Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2008):366-373.
52. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M et al: Targeting the leukemic stem cell: The Holy Grail of leukemia therapy. Leukemia (2009) 23(1):25-42.
53. Konopleva M, Tabe Y, Zeng Z, Andreeff M: Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat (2009) 12(4-5):103-113.
54. Lescuyer P, Hochstrasser D, Rabilloud T: How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res (2007) 6(9):3371-3376.